itated rapid advances in the study of receptors. Several membrane receptors have been purified and an understanding of their function at a molecular level is now being realized. Ligand-binding studies have also shown that the numbers and properties of receptors are dynamically modulated by a variety of factors, including disease states and by chronic exposure to hormones and drugs (desensitization). This has provided an important approach to understanding the molecular basis for control of drug, neurotransmitter, and hormone sensitivity. Furthermore, the discovery of diverse receptors on circulating cells has provided a direct approach to the study of these receptors in disease states in man.
Measurement of receptor binding
Radioactive analogues of hormones and drugs may be used to label binding sites on cells and in cell-membrane preparations. In each instance it is necessary to demonstrate rigorously that the binding measured reflects association of the ligand with the relevant receptor. Many sites other than receptors may bind radioactive ligands saturably, with high affinity and with definable specificity. The most important hallmark of a receptor binding site identified in a radioligand binding assay is its detailed specificity. This specificity should be virtually identical to the specificity of the physiological response that is mediated by that receptor. When stereospecificity characterizes the ability of drugs or hormones to elicit a response, it should also be expressed in the results of binding studies.
The amount of radioligand bound in a particular cell or membrane preparation is a function of the re-ceptor concentration, its affinity for the radioligand, and the concentration of the radioligand. Therefore, the determination of the amount of a radioactive ligand bound to a cell or membrane preparation at a single concentration of radioligand, a practice often encountered in the literature, provides little information about the status of the receptors and does not even distinguish between a change in receptor affinity for binding ligands and a change in the number of receptors.
Recently, there has been a lively debate in the literature as to the best way to analyze ligand-binding data. Klotz (1) [L] .
A powerful analytic approach is to use one of several computer-assisted nonlinear least squares curve fitting programs that directly apply the law of mass action to analysis of binding data (3, 4) . This method ensures a much greater degree of accuracy in the determination of dissociation constants and number of receptors, and permits objective statistical testing of good- ' Abbreviations used in this paper: B, amount of bound ligand; F, amount of free ligand. ness of fit. It can compare alternative models (e.g., one vs. multiple classes of binding sites) with selection of the "best model" based on objective statistical criteria. The direct computer-assisted statistical analysis of binding data also avoids biases and artifacts resulting from data transformations required in most graphical methods of analysis. It provides measures of the standard errors of all estimated parameters, permits simultaneous analysis of several curves, and provides the ability to statistically compare differences between binding isotherms.
General insights about membrane receptors from ligand binding studies
The number of receptors at the cell surface is not fixed. Receptor number is dynamically regulated, both by hormones and drugs that ordinarily combine with the receptors, as well as by other factors. For example, the number of s-adrenergic receptors on cells is regulated both by their natural ligands (catecholamines) as well as by other hormones such as thyroxine, glucocorticoids, and sex steroids (5) . Such regulation of receptor number in turn often controls cellular sensitivity to hormone or drug action. The most thoroughly studied such form of receptor regulation is the regulation of receptor number by ligands referred to as "down regulation." Initially described for the insulin receptors (6) and f-adrenergic receptors (7), this phenomenon has now been documented for many plasma membrane receptors (8) (9) (10) .
Several different cellular mechanisms are involved in these processes. All have in common that they are promoted by agonists but not antagonists and ultimately lead to the translocation of the surface receptors to an intracellular location. In some cases the intracellular transport is accomplished by special endocytotic vesicles that arise at the cell surface (11 Receptor-binding studies have helped to illuminate the molecular mechanisms of drug and hormone action. That receptors both bind ligands and activate biological processes is hardly a new notion. However, it had earlier been thought that only the first of these functions could be probed by ligand-binding approaches. In fact, significant insights concerning the second or "activating" function of receptors may also be obtained from such studies. One particularly fruitful approach has been the investigation and comparison of the binding characteristics of agonists and antagonists. Agonists and antagonists both bind to the same receptor, but, since agonists promote biological effects, whereas antagonists do not, it was reasoned that differences in their binding properties might provide clues as to the mechanistic basis for these differences in their effects.
The most thoroughly studied system has been the adenylate cyclase-coupled #B-adrenergic receptor. Such systems consist of three distinct molecular components (Fig. 1) is described by the equation: R + N = RN (12) . Guanine nucleotides such as GTP bind to the coupling protein and are required for activation of adenylate cyclase by hormones. Agonists promote the interaction of hormone receptor with coupling protein, which leads to adenylate cyclase activation. Antagonists do not favor formation of this complex. Since antagonists display equal affinity for the two states of the receptor, their competition curves are uniphasic and conform quite closely to what is predicted by the law of mass action for binding to a single class of sites. In contrast, agonist competition curves are biphasic but are shifted to lower affinity and become uniphasic in the presence of guanine nucleotides. Guanine nucleotides convert all the high affinity state receptors into low affinity state receptors coincident with hormone-promoted activation of the enzyme (12) . This phenomenon has been demonstrated for a wide variety of hormone, drug, and neurotransmitter receptors, which are coupled to the effector adenylate cyclase and even for some receptors where coupling to the adenylate cyclase system has not been demonstrated. An example of the latter is the receptor for chemotactic peptides on polymorphonuclear leukocytes (13) .
There are many other more and less complicated models of ligand receptor interaction. These models include allosteric or "two-state" models, various cooperative models, and divalent receptor models. In summary, ligand binding data, when carefully analyzed, can help to sort out the underlying molecular mechanisms involved and suggest further, more definitive, biochemical experiments.
In clinical investigation, a detailed understanding of normal biochemistry and physiology is often rapidly translated into increased knowledge about how various pathophysiologic circumstances alter normal processes. Since ligand-binding data may reflect molecular interactions between receptors and other components of the effector system, such data can be used to assess the status of such interactions in various physiologic, therapeutic, and pathophysiologic circumstances. For example, recent findings indicate that formation of the agonist-,B-adrenergic receptor-nucleotide regulatory protein complex is modulated by a variety of physiological and pathophysiological circumstances and that such modulation represents an important mechanism for the control of tissue sensitivity to catecholamine action (5) . Several clinically relevant conditions are associated with an attenuation of the ability of f3-adrenergic agonists to stimulate adenylate cyclase and include such diverse conditions as desensitization due to prolonged exposure to agonist, hypothyroidism, hypoadrenalism, and pseudohypoparathyroidism type IA. In each case the altered receptor responsiveness can be documented directly in agonist-binding competition curves, and is apparent as a shift in the competition curve to a lower affinity. The change in affinity is because of a decreased stability of the high affinity receptor complex. Thus, these findings suggest that the "uncoupling" observed is due to impaired interaction of hormone receptor and coupling protein to form the obligatory intermediate complex containing the agonist, the f-adrenergic receptor, and the nucleotide regulatory protein.
Modulation of the interaction between hormone receptor and coupling protein may represent a fundamentally important point of regulation in the control of tissue sensitivity to I8-adrenergic stimulation (5, 12) . In this particular example, the effector is an enzyme, adenylate cyclase, whereas in other cases it might be an ion channel or transport protein. These findings also emphasize that both receptor number and receptQr coupling are dynamically regulated. The mechanisms by which coupling of receptors to effectors, such as the coupling protein of the adenylate cyclase system, are regulated are just beginning to be elucidated. For example, recent work has suggested that covalent modification of fB-adrenergic receptors may be one mechanism leading to the receptor "uncoupling" that accompanies some forms of agonist-promoted desensitization (12 The other technique that has recently greatly facilitated elucidation of the structure of membrane receptors is photoaffinity labeling (15) . This labeling can be accomplished by the synthesis of hormone and drug analogues that contain a photoactive moiety, such as an azide group. Once such a ligand is bound to the receptors in particulate or soluble preparations, ultraviolet irradiation generates a reactive species (e.g., a nitrene) that leads to the covalent incorporation of the ligand into receptor proteins. Since many such ligands can be radioactively labeled, the size of the receptor can be assessed by polyacrylamide gel electrophoresis in sodium dodecyl sulfate and autoradiography of the gel to identify the receptor-ligand complex. Assurance that such irreversible ligands are actually bound to the receptors is obtained by documenting that other agents that combine with the receptors appropriately block incorporation of the radiolabeled irreversible ligand. Using such techniques, a variety of membrane receptors have been identified. All appear to be integral membrane glycoproteins with apparent molecular weights ranging from 30,000 to 300,000 (12, (16) (17) (18) . In somne cases, the ligand-binding site resides on a single peptide chain that comprises the active receptor, as with the P-adrenergic receptor (12) . In other cases, the binding site resides on a peptide that is noncovalently bound to other protein subunits (which presumably subserve an effector function) in an oligomeric structure. The nicotinic cholinergic receptor is an example of this type of receptor (17) . For other receptors the ligand binds to a peptide that is covalently bound to distinct peptide chains that may bear an effector activity, e.g., a protein kinase. The insulin receptor provides an example of this structural arrangement (19) .
Future prospects
Ligand-binding techniques for the study of membrane-bound receptors are now used in virtually every branch of biomedical science. Prbper application of the methodology and judicious interpretation of the data generated can provide insights well beyond the simple enumeration of the number or affinity of receptors in tissues under varying conditions. The ability to solubilize and purify the receptors has opened the way to detailed studies of their molecular structure and the functional consequences of their modification in various pathophysiological circumstances. It is reasonable to predict that within the next few years the various effectors of these receptors will also be purified and reconstituted with the isolated receptors. Such re-
